Skip to main content
OpenTrials
Completed

NCT Number: NCT02712736

Quality of Life in Patients With Primary Sclerosing Cholangitis

The purpose of this study is to assess the healthcare-related quality of life (HRQOL), the impact of risk of liver transplant and risk of malignancy on HRQOL, and the complementary and alternative medicine use in patients with PSC.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Duke University

Durham, North Carolina, 27710, United States

About this study

A cohort of adult (age ≥ 18) patients with a diagnosis of PSC will be identified. The patients will be approached about participating in the study while at their appointment, either by the investigators or someone else known to the patient. If the patient agrees, the investigators or other key personnel will then provide information about the study and obtain their informed consent to participate.

The patients who consent to participate will be sent home from the clinic with a survey to complete and return via mail in a provided addressed, stamped envelope. The survey consists of the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ), questions from the PROMIS SexFs v2.0, questions regarding perceived risk for liver transplant, cholangiocarcinoma, and colorectal carcinoma, as well as perceived overall life expectancy, and questions regarding complementary and alternative medicine use.

Demographic information and clinical data will also be obtained from the patient's electronic medical record. The study will be cross-sectional in nature, and there will be no follow-up with the subjects after the survey is completed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult (age ≥ 18) patients with PSC, confirmed by laboratory tests, imaging, and/or liver biopsy

Exclusion criteria

  • Patients <18
  • Patients who have undergone liver transplant, patients with frank hepatic encephalopathy
  • Patients with active inflammatory bowel disease (IBD) flares
  • Patients with malignancies
  • Patients unable to understand English
  • Patients refusing to participate or provide informed consent

Treatment and study plan

Quality of life survey

Other

subjects with PSC will be administered a survey to assess their quality of life

Primary outcomes

  1. Impaired quality of life as measured by questionnaire

    Time frame: Approximately 2 weeks

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Official study title

Quality of Life in Primary Sclerosing Cholangitis

Acronym: QOL in PSC

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Mar 18, 2016
Registry last updated
Jan 30, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.